Drugs In The Making
  • Shruti's Blog
  • About Shruti Bhat
  • QUALITY BLOG
  • Industry News
  • Free Ebook
  • Research Updates
    • Drug Research
    • Clinical Research
  • Contact

Drug Research Updates

Drug Research and Technology highlights

12/9/2009

0 Comments

 
Anti-clotting drugs may lower risk of prostate cancer recurrence in men undergoing radiation-
According to research presented at the American Society for Radiation Oncology,"The use of anti-clotting drugs, including aspirin, appears to lower the odds that cancer will recur in men undergoing radiation treatment for prostate cancer," in a study of 662 men with prostate cancer undergoing radiation treatment. The researchers found that "cancer recurred in only nine percent of men taking an anti-clotting medication, compared with 22 percent of those who weren't taking the drugs." Notably, "the benefit was most pronounced in men with high-risk aggressive cancers that had not yet spread (metastasized) at the time of radiation treatment." Data indicated that among this group, "cancer recurred in 18 percent of men on anticoagulants vs. 42 percent of men not taking the drugs."

Gonorrhea drug may curb tumor growth, researchers say-
According to research appearing in the Proceedings of the National Academy of Sciences, "a gonorrhea medication developed in the 1930s," called acriflavine, "may work as a cancer therapy." In a study on "mice who were engineered to develop cancer," researchers found that "the drug has the ability to stop the growth of new blood vessels, which may then curb tumor growth." The drug works by inhibiting "the function of a protein called HIF-1, which promotes new blood vessel formation."

Natalizumab may significantly reduce hospitalization rates for Crohn's disease patients-
According to an analysis of three studies by investigators at the Dartmouth-Hitchcock Medical Center, Natalizumab significantly reduces hospitalization rates during both induction and maintenance treatments for patients with moderate to severe Crohn's disease compared with placebo,.After identifying 109 "Crohn's disease–related hospitalizations, the researchers noted that "in the patients receiving natalizumab, the rate was reduced by 31 percent during the induction period and 58 percent during the maintenance period." The rates "were also reduced in a subset of patients previously treated with anti-tumor necrosis factor...therapy."

References- http://www.pharm-education.com/2009/12/drug-research-and-technology-updates_09.html

Disclaimer : The above information has been cited from literature in public domain. This is for research purpose/ dissemination of knowledge only and should not be construed as medical advise. 
0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    shruti bhat, pharmaceutical manufacturing and continuous improvement expert
    Dr. Shruti Bhat

    Pharmaceutical Manufacturing, Continuous Improvement and Business Transformation Consultant


    Picture

    how to choose business process improvement methodology
    18 business process improvement methodologies, shruti bhat

    Categories

    All
    Drug Research Updates


      Contact

    SEND
Disclaimer:

The website, blog information, audios, videos, white papers and all other associated published content on this website is the sole property of Innoworks, Canada and is under Copy Right protection. Not to be copied, distributed or used without prior authorization of the owner. The blog provides information for general knowledge sharing for community benefit and is for academic purpose only. Please give courtesy credits to respective authors in case information published here is used as a reference.
 
Additionally, information published on the blog, resource library etc. should not be considered or construed as legal and/or medical advice.  For diagnosis of an ailment, it is recommended that one seeks help of a registered medical practitioner, while medicines should be received from a registered pharmacist only. Seek advise of registered legal expert for any information pertaining law(s).

 The authors and website owner have used their best efforts in preparing this site. The information contained herein has been stated accurately to the best ability of the authors. The information contained herein is strictly for educational purposes. The author and website owner make no representation or warranties with respect to the accuracy, contrary interpretations of the subject matter herein, applicability, fitness or completeness of the contents. Therefore, if you wish to apply ideas contained on this website, you are taking full responsibility for your actions. The author and website owner specifically disclaim any liability that is incurred from the use or application of the contents sated here.

Please note that by continuing to read this site, you agree that you have read and understood this disclaimer and are continuing to read or utilize information from this site at your own responsibility and risk. Under no circumstances can you hold us responsible for any outcome or result from your having read or followed any of the expressions/suggestions/recommendations from this site.  We hope you expand your understanding and that many of the ideas and suggestions provided on this site help you. BUT we do not take on any implicit or explicit liability for anyone following any of those suggestions, ideas or advices. This is also applicable for any comments and discussions being carried out on this site.
 
For queries regarding any posted content, please feel free to contact the web administrator using contact form.
Terms & Conditions of site usage

©
2001- 2017 Copyrighted content, ALL RIGHTS RESERVED.


  • Shruti's Blog
  • About Shruti Bhat
  • QUALITY BLOG
  • Industry News
  • Free Ebook
  • Research Updates
    • Drug Research
    • Clinical Research
  • Contact